CY1118738T1 - Χρηση της ινσουλινης γλαργινη για τη μειωση ή την προληψη της καρδιαγγειακης νοσηροτητας και θνησιμοτητας σε προδιαβητικους ασθενεις - Google Patents

Χρηση της ινσουλινης γλαργινη για τη μειωση ή την προληψη της καρδιαγγειακης νοσηροτητας και θνησιμοτητας σε προδιαβητικους ασθενεις

Info

Publication number
CY1118738T1
CY1118738T1 CY20161101212T CY161101212T CY1118738T1 CY 1118738 T1 CY1118738 T1 CY 1118738T1 CY 20161101212 T CY20161101212 T CY 20161101212T CY 161101212 T CY161101212 T CY 161101212T CY 1118738 T1 CY1118738 T1 CY 1118738T1
Authority
CY
Cyprus
Prior art keywords
mortality
gargini
insulin
reduce
heart disease
Prior art date
Application number
CY20161101212T
Other languages
Greek (el)
English (en)
Inventor
Ralf Rosskamp
Hertzel Gerstein
Original Assignee
Aventisub Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventisub Llc filed Critical Aventisub Llc
Publication of CY1118738T1 publication Critical patent/CY1118738T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20161101212T 2003-01-14 2016-11-23 Χρηση της ινσουλινης γλαργινη για τη μειωση ή την προληψη της καρδιαγγειακης νοσηροτητας και θνησιμοτητας σε προδιαβητικους ασθενεις CY1118738T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43994103P 2003-01-14 2003-01-14
EP04702167A EP1589991A1 (en) 2003-01-14 2004-01-14 Long acting insulin for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type 2 diabetes

Publications (1)

Publication Number Publication Date
CY1118738T1 true CY1118738T1 (el) 2017-07-12

Family

ID=23746761

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101212T CY1118738T1 (el) 2003-01-14 2016-11-23 Χρηση της ινσουλινης γλαργινη για τη μειωση ή την προληψη της καρδιαγγειακης νοσηροτητας και θνησιμοτητας σε προδιαβητικους ασθενεις

Country Status (16)

Country Link
US (4) US7405196B2 (https=)
EP (2) EP1589991A1 (https=)
JP (1) JP5389325B2 (https=)
AU (2) AU2004206829B2 (https=)
BR (1) BRPI0406499A (https=)
CA (1) CA2512820C (https=)
CY (1) CY1118738T1 (https=)
DK (1) DK2596800T3 (https=)
ES (1) ES2604359T3 (https=)
GB (1) GB0309154D0 (https=)
HU (1) HUE031892T2 (https=)
IL (3) IL169697A (https=)
MX (1) MXPA05007470A (https=)
PT (1) PT2596800T (https=)
SI (1) SI2596800T1 (https=)
WO (1) WO2004064862A1 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
DE602004021603D1 (de) * 2003-07-25 2009-07-30 Conjuchem Biotechnologies Inc Insulinderivative mit langanhaltender wirkung und verfahren zu deren herstellung
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
CN101827626B (zh) 2008-06-13 2015-03-18 曼金德公司 干粉吸入器和用于药物输送的系统
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
US10437962B2 (en) 2008-12-23 2019-10-08 Roche Diabetes Care Inc Status reporting of a structured collection procedure
US9918635B2 (en) 2008-12-23 2018-03-20 Roche Diabetes Care, Inc. Systems and methods for optimizing insulin dosage
US10456036B2 (en) * 2008-12-23 2019-10-29 Roche Diabetes Care, Inc. Structured tailoring
US8849458B2 (en) * 2008-12-23 2014-09-30 Roche Diagnostics Operations, Inc. Collection device with selective display of test results, method and computer program product thereof
CN102265280A (zh) * 2008-12-23 2011-11-30 霍夫曼-拉罗奇有限公司 用于在收集设备上运行的结构化收集过程的实现、执行、数据收集和数据分析的管理方法和系统
US9117015B2 (en) 2008-12-23 2015-08-25 Roche Diagnostics Operations, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US20120011125A1 (en) 2008-12-23 2012-01-12 Roche Diagnostics Operations, Inc. Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
KR102584844B1 (ko) 2009-06-12 2023-10-04 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
PL2451437T3 (pl) 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
US8532933B2 (en) 2010-06-18 2013-09-10 Roche Diagnostics Operations, Inc. Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送系统和方法
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US20120173151A1 (en) 2010-12-29 2012-07-05 Roche Diagnostics Operations, Inc. Methods of assessing diabetes treatment protocols based on protocol complexity levels and patient proficiency levels
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
US8755938B2 (en) 2011-05-13 2014-06-17 Roche Diagnostics Operations, Inc. Systems and methods for handling unacceptable values in structured collection protocols
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US8766803B2 (en) 2011-05-13 2014-07-01 Roche Diagnostics Operations, Inc. Dynamic data collection
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
EP2785366A1 (en) * 2011-12-01 2014-10-08 Sanofi Insulin glargine versus metformin for the first-line treatment of early type 2 diabetes
WO2013144273A1 (en) * 2012-03-28 2013-10-03 Sanofi Basal insulin therapy
KR102264177B1 (ko) 2012-07-12 2021-06-11 맨카인드 코포레이션 건조 분말 약물 전달 시스템 및 방법
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
EP2983697B1 (en) 2013-04-03 2018-10-31 Sanofi Treatment of diabetes mellitus by long acting formulations of insulins
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
WO2016001185A1 (en) * 2014-07-02 2016-01-07 Novo Nordisk A/S Dosage regimen for the treatment of diabetes
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
WO2017108943A1 (en) * 2015-12-23 2017-06-29 Sanofi-Aventis Deutschland Gmbh Cardiac metabolic effect of lantus
WO2018096164A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
MA46890A (fr) * 2016-11-28 2021-04-28 Novo Nordisk As Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme
WO2018096162A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
US11366189B2 (en) * 2020-09-25 2022-06-21 Uih America, Inc. Systems and methods for magnetic resonance imaging
CN119833121B (zh) * 2025-01-09 2025-10-24 南通大学 一种糖尿病症状自动检测系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354331A (en) 1992-07-15 1994-10-11 Schachar Ronald A Treatment of presbyopia and other eye disorders
DE69826286T2 (de) * 1997-06-27 2005-11-24 Fujisawa Pharmaceutical Co., Ltd. Derivate mit einem aromatischen ring
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
NZ522036A (en) * 2000-04-19 2004-04-30 Borody Thomas J Compositions and therapies for hyperlipidaemia-associated disorders
MXPA03003733A (es) * 2000-10-26 2004-10-15 Fournier Lab Ireland Ltd Combinacion de fenofibrato y coenzima q10 para el tratamiento de la disfuncion endotelial.

Also Published As

Publication number Publication date
PT2596800T (pt) 2016-12-02
US20080287343A1 (en) 2008-11-20
IL169697A (en) 2011-06-30
DK2596800T3 (en) 2016-12-12
IL197739A (en) 2017-02-28
US20110281793A1 (en) 2011-11-17
AU2010202738A1 (en) 2010-07-22
US8809270B2 (en) 2014-08-19
JP5389325B2 (ja) 2014-01-15
US20130012433A1 (en) 2013-01-10
BRPI0406499A (pt) 2005-12-06
AU2004206829A1 (en) 2004-08-05
IL197739A0 (en) 2011-08-01
MXPA05007470A (es) 2005-09-21
IL208525A0 (en) 2010-12-30
WO2004064862A1 (en) 2004-08-05
EP2596800A1 (en) 2013-05-29
US7977310B2 (en) 2011-07-12
US20040229774A1 (en) 2004-11-18
IL169697A0 (en) 2007-07-04
GB0309154D0 (en) 2003-05-28
CA2512820A1 (en) 2004-08-05
EP2596800B1 (en) 2016-08-24
SI2596800T1 (sl) 2017-04-26
AU2004206829B2 (en) 2010-04-08
EP1589991A1 (en) 2005-11-02
ES2604359T3 (es) 2017-03-06
CA2512820C (en) 2013-06-04
US7405196B2 (en) 2008-07-29
AU2010202738B2 (en) 2013-12-05
JP2006515625A (ja) 2006-06-01
HUE031892T2 (en) 2017-08-28

Similar Documents

Publication Publication Date Title
CY1118738T1 (el) Χρηση της ινσουλινης γλαργινη για τη μειωση ή την προληψη της καρδιαγγειακης νοσηροτητας και θνησιμοτητας σε προδιαβητικους ασθενεις
CY1107644T1 (el) Διασφαλισμενη εναντια σε καταχρηση μορφη χορηγησης
CY1107738T1 (el) Διασφαλισμενη εναντια σε καταχρηση μορφη χορηγησης
CY1117656T1 (el) Επιλογες θεραπειας για τη νοσο του fabry
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
CY1116640T1 (el) Φαρμακευτικο παρασκευασμα που περιεχει οξυκωδονη και ναλοξονη
CY1109462T1 (el) Συνθεση και διαδικασια εκχυλιση του διαλυτη μεταλλων χρησιμοποιωντας τους παραγοντες εκχυλισης αλδοξιμη ή κετοξιμη
ATE550071T1 (de) Programmierer für ein medizinprodukt mit selektiver inaktivierung der anzeige bei telemetrie
CY1106476T1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
BRPI0408331A (pt) conjugado de polipetìdeo fisiologicamente ativo possuindo meia vida útil in vivo prolongada
ATE396738T1 (de) Verwendung von glp-2-peptiden
PA8562801A1 (es) Nuevos derivados de pirido (2,1-a) isoquinolina
CY1110669T1 (el) Χρησιμοποιηση βενζο-συγχωνευμενων ετεροκυκλικων παραγωγων σουλφαμιδιου για τη θεραπευτικη αγωγη της καταθλιψης
CY1110127T1 (el) Υποκατεστημενες 1-προπιολυλο-πιπεραζινες με χημικη συγγενεια για τον υποδοχεα mglur5 για τη θεραπεια καταστασεων πονου
CY1105941T1 (el) ΡΕΤΙΝΟΕΙΔΙΚΟΙ ΑΓΩΝΙΣΤΕΣ ΕΚΛΕΚΤΙΚΟΙ ΩΣ ΠΡΟΣ RARγ ΓΙΑ ΤΗ ΘEPΑΠΕΙΑ ΤΟΥ ΕΜΦΥΣΗΜΑΤΟΣ
IL172396A0 (en) Replikin peptides and uses thereof
CY1113789T1 (el) Συνδυασμοι απο ενεργοποιητες διαυλων καλιου και αναστολεις διαυλων νατριου ή δραστικες ουσιες που επηρεαζουν τους διαυλους νατριου για τη θεραπεια επωδυνων καταστασεων
CY1112614T1 (el) Αγωγη με κλαδριβινη για τη θεραπεια πολλαπλης σκληρυνσης
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
NL1024930A1 (nl) Spiraalvormige hartaftasting met grote pitch en met yitgebreide reconstructievensters.
DE602004015487D1 (de) Programmiergerät für medizinisches gerät mit infrarot-kommunikation
ATE382778T1 (de) Pumpenkombination
DE60230455D1 (de) Natürliche verbindung für die behandlung von diabetes, deren herstellung und verwendung
CY1105403T1 (el) Χρηση της ακετυλο-l-καρνιτινης σε συνδυασμο με τη βιοτινη για τη θepαπεια ασθενων με ινσουλινο-ανθεκτικο σακχαρωδη διαβητη τυπου 2
BRPI0417304A (pt) composição, uso e processo para produção da mesma